Inter-relationship of plasma markers of oxidative stress and thyroid hormones in schizophrenics

BMC Research Notes

Ebenezer O Ogunyemi²  Omobola A Ogundahunsi²  Moses O Akiibinu¹ 

[1] G.P.O Box 11379 Dugbe, Ibadan, Oyo State, Nigeria;Department of Chemical Pathology and Immunology, College of Health Sciences, Olabisi Onabanjo University, Ago-Iwoye, Ogun State, Nigeria

关键词: Schizophrenia;    Thyroid hormones;    Oxidative stress;   

Others  :  1166538
DOI  :  10.1186/1756-0500-5-169

 received in 2011-08-18, accepted in 2012-03-31,  发布年份 2012

【 摘 要 】

Background

The relationship of oxidative stress to thyroid hormones has not been studied in the schizophrenics. The present study determined the status and interrelationship of plasma markers of oxidative stress, nitric oxide and thyroid hormones in thirty (17 males and 13 females) newly diagnosed patients with acute schizophrenia before initiation of chemotherapy. Twenty five (13 males and 12 females) mentally healthy individuals served as controls. Patients and controls with history of hard drugs (including alcohol and cigarette), pre-diagnosis medications (e.g. antiparkinsonian/antipsychotic drugs), chronic infections, liver disease and diabetes mellitus were excluded from the study. Plasma levels of total antioxidant potential (TAP), total plasma peroxides (TPP), nitric oxide (NO), malondialdehyde (MDA), thyroxine (T4), tri-iodothyronine (T3) and thyroid stimulating hormone (TSH) were determined in all participants using spectrophotometric and enzyme linked immunosorbent assay (ELISA) methods respectively. Oxidative stress index (OSI) was calculated as the percent ratio of total plasma peroxides and total antioxidant potential.

Findings

Significantly higher plasma levels of MDA (p < 0.01), TPP (p < 0.01), OSI (p < 0.01), T3 (p < 0.01) and T4 (p < 0.05) were observed in schizophrenics when compared with the controls. The mean levels of TAP, NO and TSH were significantly lower in schizophrenics (p < 0.01) when compared with the controls. The result shows that T3 values correlate significantly with MDA (p < 0.05) and TPP (p < 0.01) in schizophrenics.

Conclusions

Higher level of TPP may enhance thyroid hormogenesis in schizophrenics. Adjuvant antioxidant therapy may be a novel approach in the treatment of schizophrenic patients.

【 授权许可】

   
2012 Akiibinu et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]John JP: Fronto - temporal dysfunction in schizophrenia, a selective review. Indian J Psychiatr 2009, 51:180-190.
• [2]Van Snellenberg JX: Working memory and long term memory deficits in schizophrenia; is there a common substrate? Psychiatry Res 2009, 174:89-96.
• [3]Horrobin D: The lipid hypothesis of schizophrenic in brain lipids and disorders in biological psychiatry. Volume 35. Edited by Skinner ER. Amsterdam: Elsevier Science; 2002::39-52.
• [4]Meyer U, Feldon J: Epidemiology driven neuro-developmental animal models of schizophrenia. Prog Neurobiol 2009, in press.
• [5]LeBee PY, Fatseas M, Denis C, Lavic E, Auriacombe M: Cannabis and psychosis; search of a causal link through a critical and systematic review. Encéphale 2009, 35:377-385.
• [6]Van Os J, Kapur S: Schizophrenia. Lancet 2009, 374:635-645.
• [7]Jeffrey M, Ryder SJ, Martin S, Hawkins SAC, Terry L, Berthelin-Baker C, Bellworthy SJ: Oral inoculation of sheep with the agent of bovine spongiform encephalopathy (BSE). I. Onset and distribution of disease-specific PrP accumulation in brain and viscera. J Comp Pathol 2001, 124:280-289.
• [8]Joshi AS, Li XC, Nimrod AC, ElSohly HN, Walker LA, Clark AM: Dihydrochalcones from Piper longicaudatum. Planta Med 2001, 67:186-188.
• [9]Moncada S, Palmer RMJ, Higgs EA: Nitric oxide physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43:109-142.
• [10]Gaston B, Drazen JM, Loscalzo J, Stanler JS: The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med 1994, 149:538-551.
• [11]Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarthy S: Inhibition of low-density lipoprotein oxidation by nitric oxide. FEBS Lett 1993, 334:170-174.
• [12]Beckman JS, Ye YZ, Anderson PG, Chen J, Accavitti MA, Tarpey MM, White CR: Extensive nitration of protein tyrosine in human atheroscerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler 1994, 375:81-88.
• [13]Dai G, Levy O, Carrasco N: Cloning and characterization of the thyroid iodide transporter. Nature 1996, 379:458-460.
• [14]De Deken X, Wang D, Dumont JE, Miot F: Characterization of ThOX proteins as components of the thyroid H2O2 -generating system. Exp Cell Res 2002, 273:187-196.
• [15]Schweizer U, Chiu J, Kohrle J: Peroxides and peroxide-degrading enzymes in the thyroid. Antioxid Redox Signal 2008, 10:1577-1592.
• [16]Taurog A: Thyroid peroxidase and thyroxine biosynthesis. Recent Prog Horm Res 1970, 26:189-247.
• [17]Chittiprols VG, Neelakantachar N, Babu SV, Reddy NA, Shetty KT, Gangadhar BN: Oxidative stress and neopterin abnormalities in Schizophrenia, A longitudinal study. J Psychiatr Res 2009, in press.
• [18]Yazici K, Yazici AE, Taneli B: Different neuro-endocrine profiles of remitted and non-remitted schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:579-584.
• [19]Kendell R, Jablensky A: Distinguishing between the validity and utility of psychiatric diagnoses. Am J Psychiatry 2003, 160:4-12.
• [20]Young DS, Pestaner LC, Gilberman U: Effects of drugs on clinical laboratory tests. Clin Chem 1975, 21:3660.
• [21]Varshney R, Kale RK: Effect of calmodulin antagonist on radiation-induced lipid peroxidation in microsomes. Int J Radiat Biol 1990, 58:733-743.
• [22]Benzie IE, Strain JJ: The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power (the FRAP assay). Anal Biochem 1996, 239:70-76.
• [23]Harma M, Harma M, Enel O: Increased oxidative stress in patients with hydatidiform mole. Swiss Med Wkly 2003, 133:563-566.
• [24]Wanchu A, Khullar M, Bhatnagar A, Sud A, Bambery P, Singh S: Pentoxiphylline Reduces Nitric Oxide Production among Patients with HIV Infection. Immunol Lett 2000, 74:121-125.
• [25]Lommen MJ, Restifo K: Trauma and post traumatic stress disorder (PTSD) in patients with schizophrenia or schizoaffective disorder. Community Ment Health J 2009, S3:24.
• [26]Kozumplik O, Uzum S, Jakovljevic M: Psychotic disorders and Comorbidity somatic illness VS side effect. Psychiatr Danub 2009, 21:361-367.
• [27]Tschoner A, Flexishhacker FWW, Ebenbichler CF: Experimental antipsycholtics and metabolic adverse effects - findings from clinical trials. Curr Opin Investig Drugs 2009, 10:1041-1048.
• [28]Dadheech G, Mishra S, Gautam S, Sharma P: Evaluation of antioxidant deficit in schizophrenia. Indian J Psychiatr 2008, 50:16-20.
• [29]Andreazza AC, Kauer-Sant' Anna M, Frey BN, Bond DJ, Kapezinski F, Young LT, Yatham LN: Oxidative stress markers in bipolar disorder; A metanalysi. J Affect Disord 2008, 111:135-144.
• [30]Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A: Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1178-1183.
• [31]Berger GE, Sinesny S, Amminger GP: Bioactive lipids in schizophrenia. Int Rev Psychiatry 2006, 18:85-98.
• [32]Suboticanec K, Vitamin C: status in schizophrenia. Bibl Nutr Dieta 1986, 38:173-181.
• [33]Dadheech G, Mishra S, Gautam S, Sharma P: Oxidative stress and ascorbic acid status in schizophrenics. SFRR-Indian Bull 2005, 4:23-25.
• [34]Dadheech G, Mishra S, Gautam S, Sharma P: Oxidative stress, α-tocopherol, ascorbic acid and reduced glutathione status in schizophrenics. Indian J Clin Biochem 2006, 21:34-38.
• [35]Whitford T: The underlying mechanisms of brain allergies. J Orthomol Med 2000, 15:5-14.
• [36]Uchida K, Mitsui M, Kawakishi S: Mono-oxygenation of N-acetylhistamine mediated by Lascorbate. Biochim Biophys Acta 1989, 991:377-379.
• [37]Straw GM, Bigelow LB, Kirch DG: Haloperidol and reduced haloperidol concentrations and psychiatric ratings in schizophrenic patients treated with ascorbic acid. J Clin Psychopharmacol 1989, 9:130-132.
• [38]Bernstein H, Bogerts B, Keilhoff G: The many faces of nitric oxide in schizophrenia. A Review. Schizophr Res 2005, 78:69-86.
• [39]Okouchi M, Ekshyyan O, Maracine M, Aw TY: Neuronal apoptosis in neurodegeneration. Antioxid Redox Signal 2007, 9:1060-1096.
• [40]Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarthy S: Inhibition of low-density lipoprotein oxidation by nitric oxide. FEBS Lett 1993, 334:170-174.
• [41]Beckman JS, Ye YZ, Anderson PG, Chen J, Accavitti MA, Tarpey MM, White CR: Extensive nitration of protein tyrosine in human atheroscerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler 1994, 375:81-88.
• [42]Oliveira JP, Zuardi AW, Hallak JE: Role of Nitric Oxide in Patients with Schizophrenia- a Systematic Review of the Literature. Curr Psychiatr Rev 2008, 4:219-227.
• [43]Zoroglu SS, Herken H, Yürekli M, Uz E, Tutkun H, Savaş HA, Bagci C, Ozen ME, Cengiz B, Cakmak EA, Dogru MI, Akyol O: The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. J Psychiatr Res 2002, 36:309-315.
• [44]Sim K, Chong SA, Chan YH, Lum NM: Thyroid dysfunction in chronic schizophrenia within a state psychiatric hospital. Ann Acad Med Singapore 2002, 1:641-644.
• [45]Baumgartner A, Pietzcker A, Gaebel W: The hypothalamic-Pituitary-thyroid-axis in patients with schizophrenia. Schizophr Res 2000, 44:23-24.